Results 221 to 230 of about 155,399 (295)
Fixation Stability as a Surrogate for Reading Abilities in Age-Related Macular Degeneration: A Perspective. [PDF]
Molin C +4 more
europepmc +1 more source
MSC‐derived exosomes deliver lnc‐AGT‐3 to vascular endothelial cells, where it binds hnRNP K in the nucleus. This interaction inhibits p53 ubiquitination, enhancing p53 stabilization and transcriptional activation of anti‐angiogenic targets TSP1. Consequently, p53‐mediated signaling is potentiated, effectively suppressing choroidal neovascularization ...
Lingjie Kong +9 more
wiley +1 more source
Brolucizumab for Wet Aged-Related Macular Degeneration Patients : too Good to be True
Tania Purbonegoro +6 more
openalex +1 more source
Abstract Purpose The demand for specialised eye care has quadrupled over the last two decades, driven by an aging population and the advent of new treatments. This surge has led to increased outsourcing by the Helsinki and Uusimaa Hospital District (HUS) Eye Hospital, initially relying on a fee‐for‐service model. This model, however, has been marked by
Susanna Moisander +7 more
wiley +1 more source
Massive Submacular Hemorrhage Following Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration. [PDF]
Kaganovski A, Rostomian N, Shrier E.
europepmc +1 more source
Progression and topographic subtypes of Terrien marginal degeneration
Abstract Purpose To report long‐term outcomes and to search for immunological and genetic risk factors in Terrien marginal degeneration (TMD). Methods Retrospective, in part prospective, hospital‐based longitudinal follow‐up study of 32 eyes of 16 Finnish patients from 2012 to 2023. Median follow‐up was 7.3 years (range, 0.3–15.2).
Minna Ruutila +8 more
wiley +1 more source
Abstract Purpose To evaluate test–retest variability (TRV) of the full‐field stimulus test (FST) in patients with retinitis pigmentosa (RP) and poor best‐corrected visual acuity (BCVA; ≤20/50 Snellen; ≥0.40 logMAR), and to assess the reliability of FST as a clinical endpoint in future RP trials.
J. S. Karuntu +2 more
wiley +1 more source
Treatment results switching from aflibercept to bevacizumab in wet age-related macular degeneration. [PDF]
Kananen F.
europepmc +1 more source
Abstract Background Intravitreal Anti‐Vascular Endothelial Growth Factor (VEGF) rescues retinal vasculatures and prevents disease progression in patients with neovascular Age‐Related Macular Degeneration (nAMD). However, systemic anti‐VEGF may increase the risk of thromboembolic related complications including stroke and TIA. This study aims to explore
A. H. Falemban +5 more
wiley +1 more source
Hydrogel-encapsulated antioxidant nanotherapeutics against age-related macular degeneration (AMD) oxidative damage. [PDF]
Xu J +5 more
europepmc +1 more source

